First‐line therapy with dacomitinib, an orally available pan‐HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of …
…, M Catanzaro, T Torelli, S Stagni, E Togliardi… - BJU …, 2018 - Wiley Online Library
Objective To harness the frontline therapy in advanced penile squamous cell carcinoma
(PSCC), for which chemotherapy exerts moderate activity but poor efficacy. Dacomitinib is …
(PSCC), for which chemotherapy exerts moderate activity but poor efficacy. Dacomitinib is …
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open …
…, N Nicolai, M Maffezzini, E Togliardi… - Investigational new …, 2014 - Springer
Despite a compelling preclinical rationale for the use of anti-angiogenic drugs in urothelial
cancer (UC), short-living responses have been observed in clinical trials. PF-03446962 is a …
cancer (UC), short-living responses have been observed in clinical trials. PF-03446962 is a …
[HTML][HTML] Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial
…, P Giannatempo, D Raggi, G Calareso, E Togliardi… - Annals of …, 2017 - Elsevier
Background Therapeutic options for patients with chemoresistant germ cell tumors (GCTs)
are limited. Pazopanib is a selective tyrosine kinase inhibitor with distinct antiangiogenic …
are limited. Pazopanib is a selective tyrosine kinase inhibitor with distinct antiangiogenic …
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer
…, P Giannatempo, G Calareso, E Togliardi… - Investigational new …, 2016 - Springer
Background Progress in developing effective salvage therapies for UC is warranted.
Alisertib is an orally available, selective inhibitor of the aurora kinase A. Methods A single …
Alisertib is an orally available, selective inhibitor of the aurora kinase A. Methods A single …
Brentuximab vedotin in CD30-expressing germ cell tumors after chemotherapy failure
…, R De Fato, E Togliardi… - Clinical …, 2016 - clinical-genitourinary-cancer.com
At present, the prognosis of patients with germ cell tumors (GCTs) in whom multiple
chemotherapy regimens have failed is frustratingly dismal, and the few chances of cure have …
chemotherapy regimens have failed is frustratingly dismal, and the few chances of cure have …
An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage …
…, E Tassi, G Grazia, R Mortarini, G Calareso, E Togliardi… - 2016 - ascopubs.org
480 Background: Prognosis of patients (pts) failing multiple chemotherapy (CT) regimens is
quite dismal. CD30 is expressed and prognostic in embryonal carcinoma, hence it is a …
quite dismal. CD30 is expressed and prognostic in embryonal carcinoma, hence it is a …
Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label …
…, P Giannatempo, G Calareso, E Togliardi… - … Oncology: Seminars and …, 2018 - Elsevier
Background Outcomes of neoadjuvant chemotherapy in patients with muscle-invasive
urothelial bladder carcinoma (MIUBC) should be improved. Sorafenib was combined with …
urothelial bladder carcinoma (MIUBC) should be improved. Sorafenib was combined with …
Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial.
…, S Stagni, M Maffezzini, A Crestani, E Togliardi… - 2014 - ascopubs.org
376 Background: Patients (pts) with germ cell tumors (GCT) who fail to be cured following
multiple chemotherapy (CT) courses (±high-dose CT) have an extremely poor prognosis …
multiple chemotherapy (CT) courses (±high-dose CT) have an extremely poor prognosis …
PS-033 Ifosfamide induced encephalopathy: prophylaxis and therapy with methylene blue
L Gambitta, E Togliardi, R Cusmai, C Della Costanza… - 2017 - ejhp.bmj.com
Background Ifosfamide is an alkylating agent effective in young patients affected by
sarcoma. Its use is limited due to severe side effects: haemorrhagic cystitis, prevented with …
sarcoma. Its use is limited due to severe side effects: haemorrhagic cystitis, prevented with …
Dacomitinib as first-line treatment of locally-advanced (LA) or metastatic penile squamous cell carcinoma (PSCC): Interim analysis of an open-label, single-group …
…, L Piva, S Stagni, G Calareso, E Togliardi… - Annals of …, 2016 - annalsofoncology.org
Background The survival results of neoadjuvant or 1st-line chemotherapy (CT) for LA or
metastatic PSCC are poor. HER pathway alterations may be a driver and a suitable …
metastatic PSCC are poor. HER pathway alterations may be a driver and a suitable …